Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase I/II trial to study the effectiveness of homoharringtonine in treating
patients who have refractory acute promyelocytic leukemia.